Biopharmaceutical News and Research

RSS

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.

8 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

Aptiv Solutions, a biopharmaceutical and medical device development services company and pioneer in adaptive clinical trial design, simulation and execution, announces its participation in a prestigious conference on adaptive clinical trials, held at the University of Tokyo on May 10th 2013.

7 May 2013

New Process Analytical Technology for pharmaceutical and chemical manufacturing industries

Process Analytical Technology (PAT) is quickly becoming an integral component in the pharmaceutical and chemical manufacturing industries. Utilizing a low latency network of powerful chemometric instruments, multivariate data analysis software, process control tools, and a central SQL database, PAT provides pharmaceutical and biopharmaceutical companies an edge over their competitors.

From Thermo Fisher Scientific Inc. 7 May 2013

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

7 May 2013

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, is now available in the United Kingdom.

29 Apr 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Thermo Fisher Scientific Inc., the world leader in serving science, today debuted several innovations in bioprocessing technologies and systems that address the evolving requirements of drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers.

From Thermo Fisher Scientific Inc. 26 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC).

22 Apr 2013

DecImmune and DSM to develop proprietary antibody therapeutic

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

22 Apr 2013

Vaccine development expensive but worthy of investment from Congress

During the last three decades, the biopharmaceutical industry has invested significantly in new and improved vaccines, and the collaborative efforts of the [CDC], [the WHO], national governments and industry have led to major progress in addressing global immunization goals and reducing illness and death due to vaccine-preventable diseases.

22 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid Drug Platform.

18 Apr 2013

IDRI, Medicago announce positive Phase I clinical trial results for avian flu pandemic vaccine

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

18 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

Biopharmaceutical News and Research

New VLP vaccine candidate produced for H7N9 virus

Targacept reports net loss of $8.1 million in first quarter 2013

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

New Process Analytical Technology for pharmaceutical and chemical manufacturing industries

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Advaxis to license its ADXS-HPV product candidate to FusionVax

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

DecImmune and DSM to develop proprietary antibody therapeutic

Vaccine development expensive but worthy of investment from Congress

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

IDRI, Medicago announce positive Phase I clinical trial results for avian flu pandemic vaccine

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

How to optimize your cell line development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News